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https://doi.org/10.1186/s12885-018-4786-7RESEARCH ARTICLE Open AccessA review of sex-related differences in
colorectal cancer incidence, screening
uptake, routes to diagnosis, cancer stage
and survival in the UK
Alan White1* , Lucy Ironmonger2, Robert J. C. Steele3, Nick Ormiston-Smith4, Carina Crawford2
and Amanda Seims1Abstract
Background: Colorectal cancer (CRC) is an illness strongly influenced by sex and gender, with mortality rates in
males significantly higher than females. There is still a dearth of understanding on where sex differences exist along
the pathway from presentation to survival. The aim of this review is to identify where actions are needed to
improve outcomes for both sexes, and to narrow the gap for CRC.
Methods: A cross-sectional review of national data was undertaken to identify sex differences in incidence,
screening uptake, route to diagnosis, cancer stage at diagnosis and survival, and their influence in the sex
differences in mortality.
Results: Overall incidence is higher in men, with an earlier age distribution, however, important sex differences
exist in anatomical site. There were relatively small differences in screening uptake, route to diagnosis, cancer
staging at diagnosis and survival. Screening uptake is higher in women under 69 years. Women are more likely to
present as emergency cases, with more men diagnosed through screening and two-week-wait. No sex differences
are seen in diagnosis for more advanced disease. Overall, age-standardised 5-year survival is similar between the
sexes.
Conclusions: As there are minimal sex differences in the data from routes to diagnosis to survival, the higher
mortality of colorectal cancer in men appears to be a result of exogenous and/or endogenous factors pre-diagnosis
that lead to higher incidence rates. There are however, sex and gender differences that suggest more targeted
interventions may facilitate prevention and earlier diagnosis in both men and women.
Keywords: Colorectal Cancer, Premature death, screening, Sex/gender difference, Routes to diagnosis, Staging,
survivalBackground
Colorectal cancer (CRC) is the UK’s third most common
cancer in men (after prostate and lung cancer) and
women (after breast and lung cancer) [1] costing the UK
approximately £1.6bn [2]. CRC is a disease that has both
biological sex differences and socio-cultural gender com-
ponents [3–10]. Greater awareness of how sex and* Correspondence: a.white@leedsbeckett.ac.uk
1Institute of Health & Wellbeing, Leeds Beckett University, Civic Quarter,
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sights into how improvements in prevention, early diag-
nosis, treatment and survival can be made.
More males develop CRC, with age-standardised rates
(ASRs) of 86.1 per 100,000 males compared to 56.9 per
100,000 female in the UK in 2014 (which equates to
22,844 male and 18,421 female new cases annually) [11].
CRC mortality rates are also higher in men (ASRs of
33.9 per 100,000 males c.f. 21.8 per 100,000 females)
[11]. Mortality rates are significantly higher for males
than for females in all age groups from 45 to 49 andle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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the male:female age-specific mortality rate ratio is
around 1.7:1 [11]. There is also a global trend for men
to have both higher incidence (746,298 vs 614,304 [20.6
vs14.3 ASR]) and mortality (373,639 vs 320,294 [10 vs
6.9 ASR]) for CRC [12].
Previous research has reported that sex differences in
CRC exist with regard to its type [13], location [5, 14,
15] and survival [16] and in the health behaviour of men
and women with regard to lifestyle-related risk factors
[17–20], awareness of risk [21], and screening behaviour
[22, 23]. This review however, critically explores sex
differences for data across the CRC cancer pathway
(screening uptake, the route to diagnosis, cancer staging
at diagnosis and survival), and how they might play a
part in the sex differences in mortality. These differences
are explored alongside a review of the literature on bio-
logical awareness and behaviour differences to give dir-
ection towards strategies to increase early detection and
reduce cancer burden and mortality.
Method
The data used for the review comprised a
cross-sectional study of CRC, compiling national data
available for the UK (or for England where UK data for
all countries combined were not available). Data were
sourced from a range of publicly available datasets (or
via personal communication where possible where data
were not published), and peer reviewed literature. The
following metrics and sources were used:
 CRC incidence rates, by age (2012–2014) and by
anatomical site (2010–2012) in the UK [11]
 Screening uptake and positivity rates of the guaiac-
based faecal occult blood test (gFOBT), for 60–
74 years olds combined and by five-year age band, in
England 2014–2015 [24]
 Routes to diagnosis data which show the proportion
of CRC patients who were diagnosed through the
different pathways up to the point of diagnosis,
England 2006–2013 [25]
 Stage at diagnosis data, England 2012 [26]
 Stage at diagnosis by route to diagnosis 2012–2013
[27]
 1 and 5-year age-standardised net survival for pa-
tients diagnosed in England 2011–2015 [28]
 Age-standardised net survival by stage at diagnosis:
one-year survival for patients diagnosed in England
2012–2014 [29], 5-year survival for patients diag-
nosed in the former Anglia Cancer Network area
2006–2010 [30]
Where available, 95% confidence intervals (CIs) were
used as per the CIs provided by data sources, andexamined for overlap to identify statistically significant
differences between sexes. Where CIs were not provided
(screening uptake/positivity rates and proportions by
stage at diagnosis), the two-sample test of proportions
was used to identify statistically significant differences
between sexes.
Results
Incidence of Colorectal cancer
In the UK, 2012–2014 incidence rates in adults aged 45
and over were significantly higher for males than females
and this gap was widest at ages 70–74 where the male:-
female incidence ratio of age-specific rates was 1.7:1 [11]
(Fig. 1).
A breakdown of CRC incidence by anatomical site
(Table 1) shows that the proportions of CRC cases in the
rectum and sigmoid colon are higher in males (31.5%
and 23.1%, respectively) than females (23.1% and 20.4%,
respectively). The proportion of cases in the caecum and
ascending colon are higher in females (17.2% and 9.8%,
respectively) than males (12.2% and 7.3%, respectively)
[11], which are harder to detect and diagnose.
Screening
Overall screening uptake is higher in women than men;
for the financial year 2014–15, uptake of gFOBT screen-
ing in England (Table 2) was higher amongst women
aged 60–74 (60.9%) than men (55.5%) (p < 0.001). By
5-year age group: uptake is higher for women aged 60–
64, 65–69 and 70–74 compared with men in the same
age bands (all p < 0.001), but this gap appears to narrow
with age. Positivity rates (proportion of adequately com-
pleted gFOBT tests coming back as ‘positive’/‘abnormal’)
are higher in men than women (p < 0.001), with the total
positivity rate for men 2.2% and for women 1.5% in the
60–74 age range [24].
Route to diagnosis
There are interesting sex differences demonstrated in
the pathway to the point of diagnosis of men and
women. For cancers diagnosed in England in 2006–
2013, a higher proportion of CRCs in males were diag-
nosed via the bowel screening program (8.1% of male
CRCs c.f. 5.1% of female CRCs) and the “Two Week
Wait” (TWW) pathway for urgent GP referrals for sus-
pected cancer (29.0% c.f. 26.6%) (Table 3) [24]. Both
these routes are associated with a higher three-year rela-
tive survival than average across all routes for CRC.
There was also a sex difference for emergency presen-
tations (EPs), the route associated with the worst sur-
vival, with more female CRCs being diagnosed via this
route than males (27.6% female CRCs c.f. 22.1% male
CRCs). This difference was greatest for patients aged
Fig. 1 Bowel Cancer (C18-C20): 2012–2014. Average Number of New Cases Per Year and Age-Specific Incidence Rates per 100,000 Population, UK
[11] (with permission to publish from CRUK)
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through EPs compared with 38.5% of males.
Sex differences in stage of cancer at diagnosis
There are small differences in the stage distribution of
CRCs at diagnosis between males and females (Table 4)
[26]. When excluding cases with an unknown stage from
the denominator, data for England in 2012 show a higher
proportion of CRCs in males diagnosed at stage I than
females (18.2% in males c.f. 16.3% in females; p < 0.001).
Conversely, more females than males were diagnosed at
stage II (28.7% in females c.f. 27.1% in males; p < 0.001).
When stage I and II are combined, there was no longer
a difference between males and females. There were noTable 1 Percentage distribution of cases diagnosed by anatomical s
Cancer site (ICD-10 code) Male
Average Case
Caecum (C18.0) 2829
Appendix (C18.1) 254
Ascending Colon (C18.2) 1691
Hepatic Flexure (C18.3) 673
Transverse Colon (C18.4) 1098
Splenic Flexure (C18.5) 539
Descending Colon (C18.6) 707
Sigmoid Colon (C18.7) 5380
Colon, Overlapping and Unspecified (C18.8-C18.9) 1153
Rectosigmoid Junction (C19) 1631
Rectum (C20) 7327
Total 23,282differences between the proportions of males and fe-
males diagnosed at stages III and IV, both separately and
combined (stage III p = 0.25, stage IV p = 0.08, com-
bined p = 0.65). Staging completeness was higher for
males than females (90.0% c.f. 87.7%; p < 0.001).
To explore this further, the routes to diagnosis data
have been combined with staging data to see how stage
distributions vary by route (Fig. 2) [27]. For patients di-
agnosed in England in 2012–2013, 32% of all patients di-
agnosed with CRC via an EP were diagnosed at stage IV,
with this proportion varying between the sexes (Fig. 2).
More male EPs were diagnosed at stage IV than female
(34% males (33–35%) c.f. 30% (29–31%) females) such
that even though more females present via an EP, malesite, by sex, UK, annual average 2010–2012 [11]
Female
s % Average Cases %
12.2% 3145 17.2%
1.1% 356 1.9%
7.3% 1790 9.8%
2.9% 616 3.4%
4.7% 1148 6.3%
2.3% 393 2.1%
3.0% 558 3.0%
23.1% 3740 20.4%
5.0% 1243 6.8%
7.0% 1089 5.9%
31.5% 4240 23.1%
100.0% 18,317 100.00%
Table 2 Screening uptake and positivity rates, England, financial
year 2014/15 [24]
Age Number invited Uptake Positivity rate
Female 60–64 893,199 58.1% 1.4%
65–69 687,690 64.3% 1.4%
70–74 524,607 61.1% 1.7%
Total 60–74 2,105,496 60.9% 1.5%
Male 60–64 885,340 49.8% 2.1%
65–69 649,180 60.1% 2.1%
70–74 477,750 59.8% 2.4%
Total 60–74 2,012,270 55.5% 2.2%
Uptake: proportion of invitees who were adequately screened (reaching a
definitive gFOBt outcome of either ‘Normal’ or ‘Abnormal’/‘Positive’) within
6 months of invitation
Positivity rate: proportion of those adequately screened who had an
abnormal/positive screening test result
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route. This might explain the finding of no overall differ-
ence in stage at diagnosis between the sexes despite
higher EP rates in women. However, a higher proportion
of female cases had an unknown stage, so difference in
stage by route should be interpreted with caution.
Out of those diagnosed via screening, more males were
diagnosed at stage I [36% males (34–37%), 32% (30–34%)
females], while females were more likely to be diagnosed
at stage II [27% (26–29%), females, 23% (22–25%) males].
There were no other differences in stage distribution
between sexes across the other routes analysed.
Survival
Overall, age-standardised one-year net CRC survival is
slightly higher for males, whilst five-year net survival isTable 3 Routes to diagnosis, by sex and age: colorectal cancer, Eng
Age
group
Sex Route
Screening TWW GP referral Other outpatient Inp
Under 50 Female 0.1% 17.2% 29.5% 9.8% 6.2
Male 0 19.6% 29.1% 9.7% 7.4
50–59 Female 0.1% 30.3% 29.0% 8.6% 6.0
Male 0.0% 31.7% 28.0% 8.4% 6.5
60–69 Female 17.7% 26.6% 21.9% 7.6% 4.2
Male 21.9% 27.3% 20.6% 7.1% 4.3
70–79 Female 4.1% 30.9% 25.9% 8.8% 4.0
Male 5.9% 32.1% 25.8% 9.0% 4.3
80–84 Female 0.2% 27.6% 25.3% 8.6% 3.5
Male 0.5% 30.5% 26.5% 9.1% 3.7
85+ Female 0.1% 19.7% 20.9% 6.7% 2.7
Male 0.1% 23.6% 23.8% 7.7% 3.0
All ages Female 5.1% 26.6% 24.6% 8.2% 4.1
Male 8.1% 29.0% 24.6% 8.3% 4.5similar for the sexes (Table 5). By age group, one-year
net survival for CRC is similar for males and females
across all ages, except for the 65–74 and 75–99 year age
groups where males have a slight advantage over females
(82.7% cf. 81.3% and 67.9% cf. 62.3%). Five-year net
survival data are similar between males and females for
all ages, except 75–99 (49.0% cf. 46.4%).
One-year age-standardised net survival at stage I and
II estimates for patients diagnosed in England in 2014
are similar for males and females (Table 6). Females di-
agnosed at stage III and IV and unknown stage have
worse survival than males.
Five-year age-standardised net survival was similar be-
tween males and females for stages I, III and IV (Table 7),
but survival at stage II was better for females (87% cf.
82% males) [30].
Discussion
The UK data reflect previous studies [15, 31, 32] in
showing that the overall incidence of bowel cancer is
higher in males than in females. This increased vulner-
ability of men to developing CRC may be due to a num-
ber of biological and gender-related (behavioural) factors
[31, 33–35]. Men are more likely to have a diet high in
red and processed meat [36], be heavier consumers of al-
cohol [37], and more likely to smoke [20]. Men also have
a greater propensity to deposit visceral fat [38] which is
associated with increased risk of CRC [39–41].
It is important to note, however, that the female sex is
more associated with hypermethylation, microsatellite
instability, BRAF V600E mutation, and CpG island
methylator phenotype (CIMP)-high, [7, 13], which are
more likely to result in the sessile serrated polyps (SSP).land 2006–2013 [25]
atient elective Emergency presentation DCO Unknown Total cases
% 31.3% 0.1% 5.9% 6847
% 27.3% 0.1% 6.8% 7356
% 20.8% 0.2% 5.1% 11,728
% 19.3% 0.1% 5.9% 16,027
% 18.4% 0.1% 3.4% 25,288
% 15.5% 0.2% 3.2% 40,734
% 23.5% 0.2% 2.7% 34,430
% 20.6% 0.2% 2.2% 48,055
% 31.8% 0.5% 2.5% 18,526
% 27.3% 0.3% 2.0% 19,508
% 44.8% 1.9% 3.2% 20,516
% 38.5% 0.9% 2.4% 14,865
% 27.6% 0.5% 3.3% 117,335
% 22.1% 0.3% 3.1% 146,545
Table 4 TNM stage of colorectal cancer at diagnosis by sex, adults aged 15–99, England, 2012 [26]
Stage Number of cases Proportion of cases Proportion of cases excluding unknows
Males Females Males Females Males Females
I 3144 2111 16.4% 14.3% 18.2% 16.3%
II 4680 3722 24.4% 25.2% 27.1% 28.7%
III 5336 3922 27.8% 26.5% 30.9% 30.2%
IV 4136 3215 21.5% 21.7% 23.9% 24.8%
Unknown 1919 1826 10.0% 12.3% – –
Total 19,215 14,796 100.0% 100.0% 100.0% 100.0%
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to be missed during colonoscopies and lead to more ag-
gressive forms of cancer [14]. Females were also found
to have higher frequency of KRAS mutations in codon
12 than males, which again are associated with more ad-
vanced adenomas [42].
Socio-economic deprivation (as based on income
domain scores) appears to disproportionally affect the
incidence rates for men - in England, incidence rates
are 13% higher for males living in the most deprived
areas compared with the least deprived, while for fe-
males the rates are similar for those living in the least
and most deprived areas [43]. This may be due to men’s
increased likelihood of a lifestyle associated with the risk
factors mentioned above in areas of socio-economic
deprivation [44, 45].
Screening
A factor relating to men’s relatively lower participation,
especially with regard to their higher overall risk of
CRC, in screening has been attributed to poorer
knowledge about cancer and screening as compared
to women, with the 2014 Cancer Awareness MeasureFig. 2 Stage at diagnosis by route to diagnosis, adults aged 15–99, Englan
‘inpatient elective) (with permission to publish from CRUK)(CAM) survey reporting that men were less likely to
be aware of the bowel screening programme than
women (p < 0.05) [46]. This lack of awareness has
been noted elsewhere, both with regard to men’s
awareness of screening generally [47, 48] and CRC
specifically [10, 49].
Encouraging men to discuss bowel screening with
their GP or partner on receipt of an invitation may im-
prove uptake [50] - the role of primary care in nudging
both men and women to take up cancer screening op-
portunities has been noted elsewhere [49, 51–53]. Send-
ing enhanced information associated with the national
screening programme has been shown to increase up-
take of gFOBT in both sexes [54] and an Australian
study showed sending men a notification letter prior to
faecal immunochemical test (FIT) screening resulted in
a 12% increase in uptake compared to those who were
not contacted in advance [55].
The UK National Screening Committee has recom-
mended the change from using gFOBT to the less oner-
ous FIT as the primary test for bowel cancer screening
in the UK - pilot studies show this improves uptake
[22, 56] and reduces the male-female gap in uptaked, 2012–2013 [27] (‘Other managed’ includes ‘other outpatient’ and
Table 5 One-year and five-year net survival, with 95% confidence intervals (CI), for colorectal cancer, for adults aged 15–99
diagnosed during 2011–2015, England, by age and sex [28]
Sex Age group Number of patients One-year survival Five-year survival
% 95% CI % 95% CI
Men Age-standardised 91,876 79.4 79.2 79.7 60.8 60.3 61.3
Un-standardised 91,876 77.7 77.4 78 59.4 58.9 60.0
15–44 2887 87.6 86.4 88.8 70.7 68.6 72.8
45–54 6214 86 85.1 86.8 63.4 61.9 64.9
55–64 17,462 85.8 85.2 86.3 67.2 66.3 68.1
65–74 28,572 82.7 82.2 83.1 66.1 65.3 66.9
75–99 36,741 67.9 67.4 68.5 49 48 50.1
Women Age-standardised 73,104 77.3 77 77.6 60.1 59.6 60.6
Un-standardised 73,104 73.7 73.4 74 57 56.5 57.6
15–44 2966 88.7 87.5 89.8 71.3 69.3 73.3
45–54 5250 86.7 85.7 87.6 66.5 64.9 68.1
55–64 11,617 86 85.3 86.6 67.9 66.8 69
65–74 18,637 81.3 80.7 81.9 65.1 64.2 66.1
75–99 34,634 62.3 61.7 62.8 46.4 45.5 47.3
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is a timely roll out of FIT across the UK countries to
benefit both men and women as soon as possible,
and reduce the sex difference.
The recently introduced bowel scope screening (BSS)
in England at the age of 55 overcomes some of the issues
associated with faecal sampling, but retains some gender
specific issues with regard to its acceptability and uptake.
It has been shown that women are less likely than men
to take up the opportunity [58, 59], with anticipated
greater discomfort, anxiety and embarrassment from the
test, and the gender of the practitioner undertaking the
test seeming to be particular barriers [60]. However,
uptake in women has been shown to be significantly
greater compared to men when invited to self-refer
(20.7% vs 8.8%; X2-test of independence - P = 0.05)
which may have been facilitated by their opportunity to
request a same-sex practitioner (requested by 100% of
female attendees vs 67% of males P < 0.05) [61],
highlighting the importance of screening programmes to
acknowledge gender specific barriers.Table 6 One-year age-standardised net survival, with 95% confidenc
for adults aged 15–99 diagnosed in England during 2014, by sex [29
Colorectal All stages Stage I
By sex Male 77% 98%
Confidence interval 77% 78% 96% 98%
Number in cohort 18,489 2990
Female 73% 98%
Confidence interval 72% 73% 97% 99%
Number in cohort 14,905 2213Sex differences in the effectiveness of screening
Although women are more likely to accept an invitation
to screening using gFOBT, they seem to benefit less as
the number needed to screen to detect a CRC is higher
in women than in men at all ages [62]. In part, this can
be explained by the discrepancy in incidence between
the sexes at the screening ages, but it is also now well
established there are more interval cancers in women,
indicating that gFOBT is less sensitive in women than in
men [63]. The reason for this latter observation is not
clear, but initial work on quantitative FIT for haemoglo-
bin has demonstrated very clearly that women have sig-
nificantly less haemoglobin in faeces than do men [64,
65]. Thus, if there was an aim to equalise the screening
positivity rate in men and women, it would be necessary
to set different thresholds for faecal haemoglobin (FHb)
concentration. However, the positive predictive value
(PPV) for women is less than for men, so that were a
lower cut-off for triggering an invitation to colonoscopy
used in women, a few more cancers might be detected
at screening, but at the cost of many more negativee intervals (CI), for colorectal cancer by TNM stage at diagnosis,
]
Stage II Stage III Stage IV Unknown
93% 89% 44% 57%
92% 93% 88% 90% 42% 45% 56% 59%
4297 4970 4244 2073
91% 85% 35% 50%
90% 92% 84% 86% 34% 37% 49% 52%
3576 3830 3353 2013
Table 7 Five-year net survival by stage, with 95% confidence
intervals (CIs), for colorectal cancer, for adults aged 15–99
diagnosed in the former Anglia Cancer Network during 2006–
2010, by sex [30]
5 Year Survival
Male (%) 95% CI Female (%) 95% CI
Stage I 94 91 97 97 95 100
Stage II 82 80 84 87 85 89
Stage III 60 57 63 61 59 64
Stage IV 7 6 9 8 6 10
All stages 61 60 63 63 62 65
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would therefore be altered by taking such an approach,
and this has not been adequately modelled. In the future
however, a risk score based on FIT-derived FHb, but in-
corporating sex and age, might address this issue.
It is not known why women have lower levels of FHb,
and why FHb has a lower PPV for colorectal neoplasia,
but it has been demonstrated that FHb concentration is
strongly correlated to both all cause and non-colorectal
cancer mortality [66], and may be acting as a
non-specific marker for health status. This is in keeping
with the observations mentioned above, that women
tend to have a healthier lifestyle and are less prone to
the deposition of visceral fat than men.Route to diagnosis
Females are typically a decade older when they develop
the condition, with a higher risk of co-morbidity [7],
which masks symptoms and more negatively affects their
survival and may explain why they have higher rates of
EP. However, Abel et al. found that even after adjusting
for age and deprivation differences, women still had
higher rates of EPs for colon and rectal cancer compared
with men [67]. This may relate to the sex difference in
distribution by anatomical site, with symptom profiles
likely to vary for CRC subsites.
It has been noted that men are generally less aware of
cancer signs and symptoms [46, 68–72]. The 2014 CAM
survey found men recalled and recognised fewer signs
and symptoms of cancer than women (p < 0.001), in-
cluding recognising persistent change in bowel/bladder
habits (p < 0.05) [46]. However, although women may
have higher levels of awareness it does not mean that
they are more likely to have shorter delays from the on-
set of symptoms until consultation, with the CAM sur-
vey showing women reported more barriers to seeing a
GP than men (p < 0.001). Delay in women is also evident
for other cancers, including breast cancer and gynaeco-
logical cancers which have received significantly more
publicity and campaign activity than CRC [73–75].Although men are usually less likely to attend pre-
ventative health checks and screening than women,
there is generally little evidence that they delay when ex-
periencing actual symptoms of ill-health [76–79]. This
also seems to be the case with regard to consultation re-
lating to CRC symptoms and fits with the results pre-
sented in this paper. Apart from shorter delays in men
seeking medical advice for rectal bleeding [80], no sex
differences in consultation have been noted for the most
positive predictive symptoms of CRC [81–84]. These in-
clude altered bowel habits with a range of other symp-
toms (including anaemia, weight loss, abdominal pain,
diarrhoea and constipation). The more serious the symp-
toms, such as vomiting, abdominal pain and the pres-
ence of obstruction, the shorter the duration of delay in
seeking consultation for both men and women, and the
greater likelihood that they would be diagnosed through
an emergency admission [67, 84, 85].
Getting partner sanction for seeking help is an import-
ant factor in early diagnosis [86]; Esteva et al. [85] and
Lobchuk et al. [87] both report that women are more
likely to push men to see their GP when they have CRC
symptoms, whereas women are more likely to wait to
see if the symptoms will clear up themselves. Ramos
et al. [88] similarly observed that women were more
likely not to have discussed their symptoms with their
partner prior to their first consultation, which impacts
on their early presentation as they procrastinate over
whether or not to report the signs.
Sex differences in stage of cancer at diagnosis
These findings are contrary to those of Nguyen et al. [8],
whose systematic review and meta-analysis exploring the
implication of sex as a risk factor for advanced neoplasia
and colorectal cancer found the pooled relative risk for
advanced cancer in men was 1.83 (95% confidence inter-
val, 1.69–1.97). The data from McPhail et al. [26] tends
to suggest there is little difference in stage at diagnosis,
with more men diagnosed at stage I.
A study by Lyratzopoulos et al. [89], of cancer data
covering 2006–2010 from the East of England suggested
that although sex was a factor in presenting with more
advanced cancer generally, it was not so marked for
CRC (including after adjustment for other demographic
factors), which is in line with our findings. An analysis
of sex disparities in cancer mortality and survival in
America also came to the conclusion that though there
was a higher death rate in men, this was more closely
linked to higher incidence than any other sex, or gender
specific factor [35].
Survival
The Eurocare 4 study found that females had a 2.2%
point survival advantage over males, especially in their
White et al. BMC Cancer  (2018) 18:906 Page 8 of 11younger years [90], for cancer deaths due to cancer of
the bowel and rectum across Europe. However, our data
is more in line with the more recent Eurocare 5 data,
which shows a negligible difference between the sexes
for colon cancer [91].
Strengths and limitations
The major strength of this review is that the data has
originated from national population based datasets so
data are representative of the population.
However, a limitation is that the data were at an aggre-
gate level and results have not been adjusted for other
demographic factors that can vary between males and fe-
males, with the exception of age where indicated. There-
fore, it is uncertain as to what degree some of the sex
differences in the data can be accounted for by sex dif-
ferences in other demographic factors. For instance,
variation in the uptake of screening and CRC outcomes
have previously been attributed to ethnicity and the indi-
vidual’s socio-economic circumstances [92–96]; this was
not able to be determined from our data. However, pre-
vious studies on screening uptake have demonstrated
that sex differences exist even after adjustment for other
factors [22, 62, 92].
A further limitation to the literature review relates to
the current state of play with regard to research on sex
and gender differences, with some studies included be-
ing of a smaller scale than would be preferable. However,
it was felt that for this review the completeness of the
overview of the state of play with regard to sex and gen-
der differences warranted their inclusion.
Conclusion
This is one of the first reviews to start to bring together
data on CRC cancer incidence, screening uptake, route
to diagnosis, cancer stage and survival specifically from
a sex and gender difference perspective. The data show
higher incidence rates in males than females. As there
are relatively small differences in the data from routes to
diagnosis to 5-year survival for males and females, it
suggests the higher CRC death rate in males is primarily
due to the higher incidence rate. The data show minimal
sex differences in survival by stage at diagnosis, which
could indicate that there are not significant sex differ-
ences in access to and effectiveness of CRC treatment.
Nevertheless, exogenous and/or endogenous sex and
gender differences are more apparent for the pathway
up to the point of diagnosis of CRC. We highlight that
bowel screening uptake is lower in men than women,
whilst a higher proportion of CRC cases in women are
diagnosed via an EP.
On balance, such differences between men and women
mean sex differences in stage distribution are relatively
small, but highlight that there could be differentapproaches focused onto these sex and gendered factors
to take to improve early diagnosis across both males and
females. Further research could focus on why incidence
rates are higher in males and how much the difference is
due to modifiable risk factors.
Further understanding of sex differences in CRC could
come from analysing data that considers colon and rec-
tal cancers separately, and further breakdowns such as
morphology. This may help understand the higher EP
rates in females, and how gFOBT/FIT screening is less
effective in females than males.Abbreviations
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